8-K: Catheter Precision Announces Warrant Repricing and $4.9 Million Gross Proceeds from Warrant Exercises

Catheter Precision has repriced existing warrants and secured approximately $4.9 million in gross proceeds through immediate exercises and prior exercises.

Summary

• Catheter Precision has repriced several series of existing warrants, including Series E, F, G, H, and I, reducing their exercise price to $0.70 per share.
• In exchange for immediate exercise of these warrants, the company will issue new Series K warrants, exercisable for twice the number of shares at $0.70 per share, but only after shareholder approval.
• The company expects to receive approximately $3.7 million in gross proceeds from the immediate exercise of these existing warrants.
• An additional $1.185 million was received from warrant exercises in the prior week under their original terms.
• The total gross proceeds from these warrant exercises is approximately $4.9 million.
• The company anticipates a pro forma outstanding share count of approximately 10.8 million after the immediate exercises, subject to beneficial ownership limitations.
• The new Series K warrants will have a term of 5.5 years from the date they become exercisable after shareholder approval.

Sentiment

Score: 6

Explanation: The warrant repricing and capital raise are positive for the company's immediate financial position, but the significant dilution and dependence on shareholder approval for the new warrants temper the overall sentiment. The company has raised capital but at the cost of significant dilution.

Positives

• The warrant repricing and inducement offer has resulted in a significant capital injection of approximately $4.9 million.
• The company has secured a commitment for the immediate exercise of a large number of existing warrants.
• The new Series K warrants provide a potential future source of capital upon exercise after shareholder approval.
• The company has registered the resale of the shares underlying the exercised warrants.

Negatives

• The exercise price of existing warrants has been significantly reduced from $30.00 and $40.00 to $0.70, potentially diluting existing shareholders.
• The new Series K warrants will further dilute shareholders if exercised.
• The new Series K warrants are not exercisable until shareholder approval is obtained, creating uncertainty.

Risks

• The company is dependent on shareholder approval for the new Series K warrants to become exercisable.
• The potential for significant dilution of existing shareholders if the new Series K warrants are exercised.
• The company is subject to a 30-day lock-up period on issuing new shares or convertible securities, with a 90-day restriction on variable rate transactions.
• The new warrants and underlying shares are being issued in a private placement and are unregistered, limiting their immediate resale.

Future Outlook

The company intends to file a registration statement for the resale of the new warrant shares within 30 days and use commercially reasonable efforts to have it declared effective within 60 to 90 days. The company will also seek shareholder approval for the exercise of the new Series K warrants at the earliest practical date.

Management Comments

• Catheter Precision is pleased to offer to you the opportunity to exercise all of the Series E Common Stock Purchase Warrants (the Series E Warrants), Series F Common Stock Purchase Warrants (the Series F Warrants), Series G Common Stock Purchase Warrants (the Series G Warrants), Series H Common Stock Purchase Warrants (CUSIP 74933X 187) (the Series H Warrants) and/or the Series I Common Stock Purchase Warrants (CUSIP 74933X 195) (the Series I Warrants and, together with the Series E Warrants, Series F Warrants, Series G Warrants and the Series H Warrants, the Existing Warrants)) of the Company set forth on the signature page hereto currently held by you (the Holder) at an Exercise Price (as defined in the Existing Warrants) of $0.70, which shall be the new exercise price of the Existing Warrants as of the date hereof.
• The Company expects to receive aggregate gross proceeds of approximately $3.7 million from the exercise of the Existing Warrants resulting in the issuance of up to an aggregate of approximately 5.3 million shares of common stock and a pro forma shares of common stock outstanding of approximately 10.8 million after giving effect to the exercise of the Existing Warrants, subject to application of applicable beneficial ownership blockers.

Industry Context

This announcement is relevant to the medical device industry, particularly companies focused on electrophysiology. The capital raise will allow Catheter Precision to continue developing and commercializing its products. The warrant repricing is a common tactic for companies to raise capital, but it can be dilutive to existing shareholders.

Comparison to Industry Standards

• Warrant repricing is a common practice for small-cap and micro-cap companies, especially in the biotech and medical device sectors, to raise capital.
• Companies like BioCardia and AtriCure have also used similar methods to raise funds, although the specific terms and conditions vary.
• The level of dilution from the new warrants is significant, which is not uncommon in these types of transactions, but it is important to consider the long-term impact on shareholder value.
• The 5.5-year term of the new warrants is relatively standard for these types of instruments.

Stakeholder Impact

• Shareholders will experience significant dilution if the new Series K warrants are exercised.
• The company's financial position is improved by the capital raise.
• The company's ability to execute its business plan is enhanced by the additional funding.

Next Steps

• The company will file a registration statement for the resale of the new warrant shares within 30 days.
• The company will seek shareholder approval for the exercise of the new Series K warrants at the earliest practical date.
• The company will work to have the registration statement declared effective within 60 to 90 days.

Key Dates

Keywords

warrant repricing, warrant exercise, Series K warrants, capital raise, share dilution, inducement offer, private placement, shareholder approval, medical device, electrophysiology